Literature DB >> 22153759

Safety and efficacy of daptomycin for the treatment of hospitalized adult patients in Taiwan with severe staphylococcal infections.

Chung-Chih Lai1, Wang-Huei Sheng, Jann-Tay Wang, Chun-Hsin Liao, Mao-Wang Ho, Chwen-Je Chen, Der-Li Chen, Ming-Uen Chou, Chien-Ming Lee, Yee-Chun Lin, Ming-Ye Pong, Shan-Chwen Chang.   

Abstract

BACKGROUND AND
PURPOSE: The safety and efficacy of treating serious infections caused by Staphylococcus aureus with daptomycin in a Taiwanese population were studied.
METHODS: A retrospective, multicenter study was performed in Taiwan between December 2007 and June 2009. This study included adult hospitalized patients who had received intravenous daptomycin therapy for infections caused by S aureus. All patients were followed until discharge from the hospital or death.
RESULTS: A total of 52 patients (males, n=44; median age: 62 years) were evaluated. Infections included complicated skin and soft-tissue infections (n=14), catheter-related bacteremia (n=14), osteomyelitis and septic arthritis (n=12), endovascular infections and endocarditis (n=11), and urinary tract infections (n=1). Overall, 47 (90.4%) patients were successfully treated and their clinical symptoms were resolved. Adverse effects related to daptomycin were detected in nine patients, but none were required to discontinue daptomycin.
CONCLUSION: The results support daptomycin as an effective and safe treatment for staphylococcal infections in Taiwanese populations.
Copyright © 2011. Published by Elsevier B.V.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22153759     DOI: 10.1016/j.jmii.2011.09.018

Source DB:  PubMed          Journal:  J Microbiol Immunol Infect        ISSN: 1684-1182            Impact factor:   4.399


  5 in total

1.  Self-enhanced targeted delivery of a cell wall- and membrane-active antibiotics, daptomycin, against staphylococcal pneumonia.

Authors:  Hong Jiang; Meimei Xiong; Qiuyan Bi; Ying Wang; Chong Li
Journal:  Acta Pharm Sin B       Date:  2016-06-11       Impact factor: 11.413

2.  Epidemiology and Outcomes of Complicated Skin and Soft Tissue Infections among Inpatients in Southern China from 2008 to 2013.

Authors:  Xiaoyan Li; Yunqin Chen; Weiguo Gao; Wenwei Ouyang; Jia Wei; Zehuai Wen
Journal:  PLoS One       Date:  2016-02-26       Impact factor: 3.240

3.  Safety and efficacy of high-dose daptomycin as salvage therapy for severe gram-positive bacterial sepsis in hospitalized adult patients.

Authors:  Chung-Chih Lai; Wang-Huei Sheng; Jann-Tay Wang; Aristine Cheng; Yu-Chung Chuang; Yee-Chun Chen; Shan-Chwen Chang
Journal:  BMC Infect Dis       Date:  2013-02-04       Impact factor: 3.090

4.  Safety of high-dose daptomycin in patients with severe renal impairment.

Authors:  Chih-Hsun Tai; Chi-Hao Shao; Chen-You Chen; Shu-Wen Lin; Chien-Chih Wu
Journal:  Ther Clin Risk Manag       Date:  2018-03-13       Impact factor: 2.423

5.  Daptomycin to bone and joint infections and prosthesis joint infections: a systematic review.

Authors:  João Paulo Telles; Juliette Cieslinski; Felipe Francisco Tuon
Journal:  Braz J Infect Dis       Date:  2019-06-14       Impact factor: 3.257

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.